Cargando…

SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)

Esophageal cancer is an aggressive tumor, and is the sixth-leading cause of death from cancer. Incidence is rising in Spain, particularly among men. Two main pathological different subtypes have been described: squamous cell carcinoma and adenocarcinoma. Growing evidence of their epidemiology and mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández-Montes, Ana, Alcaide, Julia, Alsina, María, Custodio, Ana Belén, Franco, Lourdes Fernández, Gallego Plazas, Javier, Gómez-Martín, Carlos, Richart, Paula, Rivera, Fernando, Martin-Richard, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986732/
https://www.ncbi.nlm.nih.gov/pubmed/35347573
http://dx.doi.org/10.1007/s12094-022-02801-2
_version_ 1784682594477015040
author Fernández-Montes, Ana
Alcaide, Julia
Alsina, María
Custodio, Ana Belén
Franco, Lourdes Fernández
Gallego Plazas, Javier
Gómez-Martín, Carlos
Richart, Paula
Rivera, Fernando
Martin-Richard, Marta
author_facet Fernández-Montes, Ana
Alcaide, Julia
Alsina, María
Custodio, Ana Belén
Franco, Lourdes Fernández
Gallego Plazas, Javier
Gómez-Martín, Carlos
Richart, Paula
Rivera, Fernando
Martin-Richard, Marta
author_sort Fernández-Montes, Ana
collection PubMed
description Esophageal cancer is an aggressive tumor, and is the sixth-leading cause of death from cancer. Incidence is rising in Spain, particularly among men. Two main pathological different subtypes have been described: squamous cell carcinoma and adenocarcinoma. Growing evidence of their epidemiology and molecular differences explains their different response to novel treatments, and they are therefore likely to be treated as two separate entities in the near future. The best results are obtained with a multidisciplinary therapeutic strategy, and the introduction of immunotherapy is a promising new approach that will improve prognosis. In these guidelines, we review the evidence for the different methods of diagnosis and therapeutic strategies that form the basis of our standard of care.
format Online
Article
Text
id pubmed-8986732
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-89867322022-04-22 SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021) Fernández-Montes, Ana Alcaide, Julia Alsina, María Custodio, Ana Belén Franco, Lourdes Fernández Gallego Plazas, Javier Gómez-Martín, Carlos Richart, Paula Rivera, Fernando Martin-Richard, Marta Clin Transl Oncol Clinical Guides in Oncology Esophageal cancer is an aggressive tumor, and is the sixth-leading cause of death from cancer. Incidence is rising in Spain, particularly among men. Two main pathological different subtypes have been described: squamous cell carcinoma and adenocarcinoma. Growing evidence of their epidemiology and molecular differences explains their different response to novel treatments, and they are therefore likely to be treated as two separate entities in the near future. The best results are obtained with a multidisciplinary therapeutic strategy, and the introduction of immunotherapy is a promising new approach that will improve prognosis. In these guidelines, we review the evidence for the different methods of diagnosis and therapeutic strategies that form the basis of our standard of care. Springer International Publishing 2022-03-26 2022 /pmc/articles/PMC8986732/ /pubmed/35347573 http://dx.doi.org/10.1007/s12094-022-02801-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Guides in Oncology
Fernández-Montes, Ana
Alcaide, Julia
Alsina, María
Custodio, Ana Belén
Franco, Lourdes Fernández
Gallego Plazas, Javier
Gómez-Martín, Carlos
Richart, Paula
Rivera, Fernando
Martin-Richard, Marta
SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)
title SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)
title_full SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)
title_fullStr SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)
title_full_unstemmed SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)
title_short SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)
title_sort seom-gemcad-ttd clinical guideline for the diagnosis and treatment of esophageal cancer (2021)
topic Clinical Guides in Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986732/
https://www.ncbi.nlm.nih.gov/pubmed/35347573
http://dx.doi.org/10.1007/s12094-022-02801-2
work_keys_str_mv AT fernandezmontesana seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021
AT alcaidejulia seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021
AT alsinamaria seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021
AT custodioanabelen seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021
AT francolourdesfernandez seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021
AT gallegoplazasjavier seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021
AT gomezmartincarlos seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021
AT richartpaula seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021
AT riverafernando seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021
AT martinrichardmarta seomgemcadttdclinicalguidelineforthediagnosisandtreatmentofesophagealcancer2021